Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3059% below fair value
$15.40−0.08 (-0.52%)
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
Aurinia Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Aurinia Pharmaceuticals's price to sales ratio was 6.9× on Nov 11, 2026, against 8.0× a year earlier. Over the last 5 years it ranged from 4.1× to 41.0×, with a median of 6.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.9× | −1.0 |
| 2025 | Dec 31, 2025 | 7.9× | +2.1 |
| 2024 | Dec 31, 2024 | 5.8× | −2.3 |
| 2023 | Dec 29, 2023 | 8.1× | +3.4 |
| 2022 | Dec 30, 2022 | 4.8× | −36.3 |
| 2021 | Dec 31, 2021 | 41.0× | – |
See a number that looks wrong?